Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Celltrion, Inc.    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
05/26/2020 05/27/2020 05/28/2020 05/29/2020 06/01/2020 Date
214500 213000 211000 213500 227500 Last
482616 591531 716376 660287 3410230 Volume
-0.23% -0.70% -0.94% +1.18% +6.56% Change
Financials
Sales 2020 1 643 B 1,34 B 1,34 B
Net income 2020 504 B 0,41 B 0,41 B
Net cash position 2020 400 B 0,33 B 0,33 B
P/E ratio 2020 60,3x
Yield 2020 0,01%
Sales 2021 1 943 B 1,59 B 1,59 B
Net income 2021 631 B 0,51 B 0,51 B
Net cash position 2021 805 B 0,66 B 0,66 B
P/E ratio 2021 48,5x
Yield 2021 0,01%
Capitalization 30 423 B 24 843 M 24 825 M
EV / Sales 2020 18 521x
EV / Sales 2021 15 659x
Nbr of Employees 908
Free-Float 55,7%
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
05/05CELLTRION : Teva and Celltrion Healthcare Announce the Launch of TRUXIMA Injecti..
AQ
04/05CELLTRION : Shares Rise on Covid-19 Treatment Progress
DJ
03/17CELLTRION : Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA ..
AQ
2019CELLTRION : 3Q Net Profit Rose 13% on Year
DJ
2019CELLTRION : and Lonza Sign Contract to Manufacture Remsima Drug Substance
AQ
2019Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
2019VEEVA : Celltrion Adopts Veeva Vault eTMF for Greater Visibility into Trial Acti..
AQ
2019CELLTRION : Partners with the Canadian Biotech Company, iProgen Biotech to Devel..
BU
2019Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
2019SOUTH KOREA'S CELLTRION AIMS TO SET : chairman
RE
2018FDA Approves Herceptin Biosimilar Herzuma
DJ
2018CELLTRION : European Medicines Agency Accepts Extension Marketing Authorisation ..
BU
2018FDA Approves Celltrion's Truxima As Biosimilar to Genentech's Rituxan
DJ
2018CELLTRION : Signs 'Incubation' Agreement with Emory University for Development o..
BU
2018Roche steps up efficiency drive to take sting out of biosimilars
RE
More news
News in other languages on CELLTRION, INC.
05/05CELLTRION : Teva and Celltrion Healthcare Announce the Launch of TRUXIMA Injecti..
04/05CELLTRION : Shares Rise on Covid-19 Treatment Progress
03/17CELLTRION : Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA ..
2019CELLTRION : 3Q Net Profit Rose 13% on Year
2019CELLTRION : and Lonza Sign Contract to Manufacture Remsima Drug Substance
More news
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 219 764,71 KRW
Last Close Price 227 500,00 KRW
Spread / Highest target 31,9%
Spread / Average Target -3,40%
Spread / Lowest Target -51,6%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Jung-Jin Seo Chairman
Ho-Seop Lee Finance Director
Dong-Il Kim Independent Director
Joseph Lee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.25.69%24 843
LONZA GROUP33.49%36 428
IQVIA HOLDINGS INC.-3.30%28 532
SEATTLE GENETICS, INC.39.17%27 527
MODERNA, INC.217.89%24 177
INCYTE CORPORATION16.53%22 118